



10533025 - GAU: 1655

PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 13

Application Number	10/533,025
Filing Date	November 20, 2006
First Named Inventor	Stephen Behr, et al.
Art Unit	1655
Examiner Name	Qiuwen Mi
Attorney Docket Number	20CE-144430

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		CA 406,408	07-28-1942	Tannin Corp./Shelton	
		EP 0 870 507 A1	10-14-1998	Farmo-Nat Ltd./Levin	
		GB 544,615	04-21-1942	Tannin Corp./Shelton	
		JP 03287532 (abstract)	12-18-1991	Daicel Chemical Ind.	
		JP 2002-087973 (abstract and copy)	03-27-2002	Kao Corp./Oji Paper	
		WO 2004/019961 A1	03-11-2004	Bio-Pharmacopae Design Int'l. Inc./Cyr	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional) <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kinds of document by the appropriate symbols as indicated on the document under WIPO Standard ST 15 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /QM/

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

**Complete if Known**

Application Number	10/533,025
Filing Date	November 20, 2006
First Named Inventor	Stephen Behr, et al.
Art Unit	1655
Examiner Name	Qiuwen Mi
Attorney Docket Number	20CF-144430

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ARAKAWA, Kazuhito, et al. "Multifunctional Anti-Angiogenic Activity of the Cyclic Peroxide Ano-2 with Antitumor Activity," <i>Int. J. Cancer</i> , 2002, pp. 220-227, Vol. 100, Wiley-Liss, Inc., UICC.	
		BERGERS, Gabriele, et al. "Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis," <i>Nature Cell Biology</i> , October 2000, pp. 737-744, Vol. 2, Macmillan Magazines Ltd., <a href="http://cellbio.nature.com">http://cellbio.nature.com</a> .	
		BOEHM, Marcus F., et al. "Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis – Retinoids: biological function and use in the treatment of dermatological diseases," <i>Exp. Opin. Invest. Drugs</i> , 1995, pp. 593-612, Vol. 4 (7), Ashley Publications Ltd., ISSN 1354-3784.	
		GROSS, Stephen C., et al. "Antineoplastic Activity of <i>Solidago virgaurea</i> on Prostatic Tumor Cells in an SCID Mouse Model," <i>Nutrition and Cancer</i> , 2002, pp. 76-81, Vol. 43, No. 1, Lawrence Erlbaum Associates, Inc.	
		KIM, Bae-Hwan, et al. "The mechanism of retinol-induced irritation and its application to anti-irritant development," <i>Toxicology Letters</i> , 9/1/2003, pp. 65-73, Vol. 146, Elsevier Ireland Ltd.	
		KLIGMAN, A.M., et al. "Topical retinol improves cellulite," <i>Journal of Dermatological Treatment</i> , 1999, pp. 119-125, Vol. 10, JDT, ISSN 0954-6634.	
		KRAUS, Josef, et al. (abstract). "Antitumor polysaccharides from <i>Solidago</i> species," <i>Deutsche Apotheker Zeitung</i> , 12/26/1986, pp. 2045-9, Vol. 126 (38), Pharm. Biol., Univ. Regensburg, Regensburg, Germany, ISSN: 0011-9857.	
		LIOTTA, L.A., et al. "Metastatic potential correlates with enzymatic degradation of basement membrane collagen," <i>Nature</i> , 3/6/1980, pp. 67-68, Vol. 284, Macmillan Journals Ltd., Nature Publishing Group.	
		NAKAHARA, Hirokazu, et al. "Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion," <i>Proc. Natl. Acad. Sci. USA</i> , July 1997, pp. 7959-7964, Vol. 94, The National Academy of Sciences.	
		PARK, Moon-Taek, et al. "Glucocorticoid Receptor-induced Down-regulation of MMP-9 by Ginseng Components, PD and PT Contributes to Inhibition of the Invasive Capacity of HT1080 Human Fibrosarcoma Cells," <i>Molecules and Cells</i> , 1999, pp. 476-483, Vol. 9, No. 5, Springer-Verlag.	

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is estimated to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed under 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

W02-WEST:ILKBW/1449B/PTO

ALL PREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /QM/

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number 10/533,025
				Filing Date November 20, 2006
				First Named Inventor Stephen Behr, et al.
				Art Unit 1655
				Examiner Name Qiuwen Mi
(Use as many sheets as necessary)				Attorney Docket Number 20CF-144430
Sheet	3	of	3	

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SUTHAR, A.C., et al. "A review on ginger ( <i>Zinger officinale</i> ): Pre-clinical and clinical trials," <i>Indian Journal of Traditional Knowledge</i> , January 2002, pp. 51-61, Vol. 2 (1).	
		VARANI, James, et al. "Molecular Mechanisms of Intrinsic Skin Aging and Retinoid-Induced Repair and Reversal," <i>JID Symposium Proceedings</i> , 1998, pp. 57-60, Vol. 98, The Society for Investigative Dermatology, Inc.	
		International Search Report for International Application No. PCT/CA2002/00285 dated July 23, 2002, European Patent Office.	
		Office Action for US Patent Application No. 10/091,331 dated October 10, 2002.	
		Office Action for US Patent Application No. 10/091,331 dated March 21, 2003.	
		Office Action for US Patent Application No. 10/091,331 dated November 14, 2003.	
		Office Action for US Patent Application No. 10/091,331 dated July 27, 2004.	
		Office Action for US Patent Application No. 10/526,387 dated May 2, 2008.	
		Office Action for US Patent Application No. 11/577,292 dated October 19, 2009.	
		Office Action for US Patent Application No. 12/263,114 dated September 23, 2009.	

Examiner Signature	/Qiuwen Mi/	Date Considered	05/24/2010
--------------------	-------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.